India-based pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced on Monday that its wholly owned subsidiary, Nanomi BV, has entered into a definitive agreement to acquire VISUfarma BV, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP.

This move will allow Lupin to tap into the ophthalmology market, which is showing strong growth driven by an ageing global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care. The merger of the two businesses will allow Lupin to provide a complete range of products in the areas of dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and highly focused nutraceuticals prescribed by ophthalmologists.

Lupin expects this acquisition to be accretive to its growth and margin profile.

Subject to certain closing conditions, the transaction is projected to close by the end of 2025.